These results demonstrated that some specific mutations could cause loss-of-function and thus XLSA, along with loss of succinyl-CoA synthase binding, while others resulted in gain-of-function by releasing intrinsic inhibition of ALAS2 by its carboxyl-terminus, thus causing XLP. Here, ALAS2 is linked to X-linked lymphoproliferative disease.